News & media

Topic: Imaging Analysis

Demystifying How Images Are Managed Between February 2017 and January 2018, ~41.4 million diagnostic imaging tests were performed in England[i]. That so many imaging tests were performed in a country with a population of ~55.3 million[ii] provides a small snapshot of the sheer volume of imaging data generated globally. As medical imaging has advanced in the digital age, so has managing and sharing the generated data. In this post, we provide a brief overview…

Immunotherapy Update: Recent Advances in CAR T-cell Therapy As a measure of its promise, chimeric antigen receptor (CAR) T-cell therapy – where patients’ own immune cells are collected, genetically changed and used to treat their cancer – is the American Society of Clinical Oncology (ASCO) Advance of the Year for 2018.[i] This approach represents an exciting innovation that has the potential to transform cancer care.[ii] CAR T-cell therapy is clinically the most advanced of…

The Value of Standardized Quality and Performance Metrics in Clinical Trials It’s not just tumor measurements that matter! Quality and Performance Measurements are critical too. Imaging biomarker metrics are not the only measurements that matter in oncology imaging trials. Quality and performance metrics are just as important and necessary for running a successful clinical trial with image analysis metrics as the endpoints. Biopharma organizations optimize clinical trials by operationalizing both quality and performance metrics. …

Different Types of Imaging Criteria: Morphological Measures In oncology clinical trials, therapy is generally assessed using imaging response criteria involving imaging biomarkers. Imaging response criteria are used to define a “treatment response” status, used by the radiologist to evaluate whether the response to therapy is complete or partial or conversely, if the disease is not responding or even progressing. Imaging biomarkers are characteristics extracted from images under study and may vary with tumor or…